Market Research Logo

Rare Neurological Disease Treatment Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2026)

Rare Neurological Disease Treatment Market: Global Industry Analysis (2012 - 2016) & Opportunity Assessment (2017 - 2026)

Majority of rare diseases at present have none or little effective procedures of diagnosis & treatment, which can be partly attributed to absence of funding toward researches on rare disease pathogenesis and lack of representative patients. Rare neurological disease are among major types of rare diseases with ineffective diagnoses and treatment options. According to WHO, 1 in 10 individuals are expected to be diagnosed with rare neurological disorder in their lifetime. Brain diseases are considered to be one of the major determinants of the neurological disease prevalence worldwide, with early intervention being the only key to prevent or curtail long-term morbidity and relevant healthcare costs.

However, diagnosis of rare neurological diseases entails several barricades including lack of intelligence and awareness about such diseases within the common medical community. This has further resulted into delayed diagnosis, and sometimes misdiagnosis, as highlighted in the book about rare diseases compiled by European Organization for Rare Diseases (EURORDIS), co-funded by European Commission. According to the publication, patients suffering from rare neurological diseases experience challenges in accessing treatment services on the coattails of lack of referral.

Spreading awareness about these diseases along with increasing their visibility are key initiatives taken by various governments worldwide for speeding up diagnostic processes and provide affected families with access to proper counselling and treatment options. A recently published report of Future Market Insights foresees the global rare neurological disease treatment market to record a spectacular growth between the period 2017 and 2026. Revenues from treatment of rare neurological disorders worldwide are poised to surpass US$ 12,000 Mn by 2026-end.

North America to Remain Largest Revenue Contributor to the Market

In North America, rare neurological conditions are considered to a major healthcare concern, although fewer individuals are currently affected by the disease. Complexity of these diseases, along with their inadequacy in treatment options have led to disproportionate share of spending in healthcare. Drug companies in North America are conducting robust researches in rare diseases, however they face difficulties related to cost of treatment development related to small or geographically dispersed populations.

Government and healthcare institutes in North America are therefore collaborating to develop a robust research network, in order to facilitate data sharing, enrollment in trials & studies, and advancement in rare diseases. This will further influence the rare neurological disease treatment market in North America. The report estimates North America to remain the largest revenue contributor to the market.

Discrepancies in R&D Funding for Rare Neurological Disease Linked with Shortage in Healthcare Provision

Management of rare neurological diseases and provision of effective therapies represent an economic and social burden on several nations. Treatment options for patients affected with rare neurological conditions continue to be limited. Discrepancies in funding for R&D associated with treatment & prevention of these diseases is mainly linked with shortfall in the healthcare provision that reflects both shortage of material sources and suboptimal training exercises of clinicians apropos brain disorders.

Although there have been notable advancements in treatment of rare neurological diseases, these are not completely curative. Governments across the globe are therefore making significant improvements in their healthcare systems to render their management to be multidisciplinary, holistic, and to include supportive and palliative care. Establishing centers of expertise, which specialize in diagnosis, treatment & care of patients affected from rare neurological diseases, is a key focus area for most of the developed and developing countries across the globe.

Key players fuelling growth of the global rare neurological disease treatment market, as identified by the report, include Pfizer Inc., Allergan Plc, Novartis AG, Bayer Aktiengesellschaft, Medtronic Plc, Sanofi, Johnson & Johnson, and Teva Pharmaceutical Industries Limited.


1. Global Economic Outlook
2. Global Rare Neurological Disease Treatment Market - Executive Summary
3. Global Rare Neurological Disease Treatment Market Overview
3.1. Introduction
3.1.1. Global Rare Neurological Disease Treatment Market Taxonomy
3.1.2. Global Rare Neurological Disease Treatment Market Definition
3.2. Global Rare Neurological Disease Treatment Market Size (US$ Mn) and Forecast, 2012-2026
3.2.1. Global Rare Neurological Disease Treatment Market Y-o-Y Growth
3.3. Global Rare Neurological Disease Treatment Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. USA, EU & Japan Orphan Designations per Year & Cumulative (1983 – 2016)
3.7. Worldwide Top 20 Orphan Drug Manufacturers (2016 – 2022)
3.8. Wheel of Fortune
3.9. Rare Disease Key Regulations
3.9.1. Rare Disease Key Regulations: North America
3.9.2. Rare Disease Key Regulations: Latin America
3.9.3. Rare Disease Key Regulations: Europe
3.9.4. Rare Disease Key Regulations: Asia Pacific
3.9.5. Rare Disease Key Regulations: Middle East & Africa
3.10. Forecast Scenario
3.11. PEST Analysis
3.12. Porte's Five Forces Analysis
3.13. Market Positioning and Behavioral Assessment
3.14. Investment Feasibility Assessment
3.15. Competitor Market Footprint Matrix
3.16. Key Participants Market Presence (Intensity Map) By Region
4. Global Rare Neurological Disease Treatment Market Analysis and Forecast 2012-2026
4.1. Global Rare Neurological Disease Treatment Market Size and Forecast By Indication, 2012-2026
4.1.1. Alzheimer’s Disease Market Size and Forecast, 2012-2026
4.1.1.1. Revenue (US$ Mn) Comparison, By Region
4.1.1.2. Market Share Comparison, By Region
4.1.1.3. Y-o-Y growth Comparison, By Region
4.1.2. Narcolepsy Market Size and Forecast, 2012-2026
4.1.2.1. Revenue (US$ Mn) Comparison, By Region
4.1.2.2. Market Share Comparison, By Region
4.1.2.3. Y-o-Y growth Comparison, By Region
4.1.3. Multiple Sclerosis Market Size and Forecast, 2012-2026
4.1.3.1. Revenue (US$ Mn) Comparison, By Region
4.1.3.2. Market Share Comparison, By Region
4.1.3.3. Y-o-Y growth Comparison, By Region
4.1.4. Amyotrophic Lateral Sclerosis Market Size and Forecast, 2012-2026
4.1.4.1. Revenue (US$ Mn) Comparison, By Region
4.1.4.2. Market Share Comparison, By Region
4.1.4.3. Y-o-Y growth Comparison, By Region
4.1.5. Other Indications Market Size and Forecast, 2012-2026
4.1.5.1. Revenue (US$ Mn) Comparison, By Region
4.1.5.2. Market Share Comparison, By Region
4.1.5.3. Y-o-Y growth Comparison, By Region
4.2. Global Rare Neurological Disease Treatment Market Size and Forecast By Drug Type, 2012-2026
4.2.1. Biologics Market Size and Forecast, 2012-2026
4.2.1.1. Revenue (US$ Mn) Comparison, By Region
4.2.1.2. Market Share Comparison, By Region
4.2.1.3. Y-o-Y growth Comparison, By Region
4.2.2. Organic Compounds Market Size and Forecast, 2012-2026
4.2.2.1. Revenue (US$ Mn) Comparison, By Region
4.2.2.2. Market Share Comparison, By Region
4.2.2.3. Y-o-Y growth Comparison, By Region
4.3. Global Rare Neurological Disease Treatment Market Size and Forecast By Mode of Administration, 2012-2026
4.3.1. Injectable Market Size and Forecast, 2012-2026
4.3.1.1. Revenue (US$ Mn) Comparison, By Region
4.3.1.2. Market Share Comparison, By Region
4.3.1.3. Y-o-Y growth Comparison, By Region
4.3.2. Oral Market Size and Forecast, 2012-2026
4.3.2.1. Revenue (US$ Mn) Comparison, By Region
4.3.2.2. Market Share Comparison, By Region
4.3.2.3. Y-o-Y growth Comparison, By Region
4.3.3. Others Market Size and Forecast, 2012-2026
4.3.3.1. Revenue (US$ Mn) Comparison, By Region
4.3.3.2. Market Share Comparison, By Region
4.3.3.3. Y-o-Y growth Comparison, By Region
4.4. Global Rare Neurological Disease Treatment Market Size and Forecast By Distribution Channel, 2012-2026
4.4.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
4.4.1.1. Revenue (US$ Mn) Comparison, By Region
4.4.1.2. Market Share Comparison, By Region
4.4.1.3. Y-o-Y growth Comparison, By Region
4.4.2. Retail Pharmacies Market Size and Forecast, 2012-2026
4.4.2.1. Revenue (US$ Mn) Comparison, By Region
4.4.2.2. Market Share Comparison, By Region
4.4.2.3. Y-o-Y growth Comparison, By Region
4.4.3. Online Pharmacies Market Size and Forecast, 2012-2026
4.4.3.1. Revenue (US$ Mn) Comparison, By Region
4.4.3.2. Market Share Comparison, By Region
4.4.3.3. Y-o-Y growth Comparison, By Region
5. North America Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
5.1. North America Outlook
5.2. North America Parent Market Outlook
5.3. North America Target Market Outlook
5.4. Revenue (US$ Mn) Comparison, By Country
5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
5.5. Revenue (US$ Mn) Comparison, By Indication
5.6. Revenue (US$ Mn) Comparison, By Drug Type
5.7. Revenue (US$ Mn) Comparison, By Mode of Administration
5.8. Revenue (US$ Mn) Comparison, By Distribution Channel
6. Latin America Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
6.1. Latin America Outlook
6.2. Latin America Parent Market Outlook
6.3. Latin America Target Market Outlook
6.4. Revenue (US$ Mn) Comparison, By Country
6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
6.5. Revenue (US$ Mn) Comparison, By Indication
6.6. Revenue (US$ Mn) Comparison, By Drug Type
6.7. Revenue (US$ Mn) Comparison, By Mode of Administration
6.8. Revenue (US$ Mn) Comparison, By Distribution Channel
7. Europe Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
7.1. Europe Outlook
7.2. Europe Parent Market Outlook
7.3. Europe Target Market Outlook
7.4. Revenue (US$ Mn) Comparison, By Country
7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026
7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026
7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026
7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
7.5. Revenue (US$ Mn) Comparison, By Indication
7.6. Revenue (US$ Mn) Comparison, By Drug Type
7.7. Revenue (US$ Mn) Comparison, By Mode of Administration
7.8. Revenue (US$ Mn) Comparison, By Distribution Channel
8. Japan Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
8.1. Japan Outlook
8.2. Japan Parent Market Outlook
8.3. Japan Target Market Outlook
8.4. Japan Market Size and Forecast (US$ Mn), 2012-2026
8.5. Revenue (US$ Mn) Comparison, By Indication
8.6. Revenue (US$ Mn) Comparison, By Drug Type
8.7. Revenue (US$ Mn) Comparison, By Mode of Administration
8.8. Revenue (US$ Mn) Comparison, By Distribution Channel
9. APEJ Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
9.1. APEJ Outlook
9.2. APEJ Parent Market Outlook
9.3. APEJ Target Market Outlook
9.4. Revenue (US$ Mn) Comparison, By Country
9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
9.4.3. Thailand Market Size and Forecast (US$ Mn), 2012-2026
9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
9.5. Revenue (US$ Mn) Comparison, By Indication
9.6. Revenue (US$ Mn) Comparison, By Drug Type
9.7. Revenue (US$ Mn) Comparison, By Mode of Administration
9.8. Revenue (US$ Mn) Comparison, By Distribution Channel
10. MEA Rare Neurological Disease Treatment Market Size and Forecast, 2012-2026
10.1. MEA Outlook
10.2. MEA Parent Market Outlook
10.3. MEA Target Market Outlook
10.4. Revenue (US$ Mn) Comparison, By Country
10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
10.4.3. Nigeria Market Size and Forecast (US$ Mn), 2012-2026
10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
10.5. Revenue (US$ Mn) Comparison, By Indication
10.6. Revenue (US$ Mn) Comparison, By Drug Type
10.7. Revenue (US$ Mn) Comparison, By Mode of Administration
10.8. Revenue (US$ Mn) Comparison, By Distribution Channel
11. Global Rare Neurological Disease Treatment Market Company Share, Competition Landscape and Company Profiles
11.1. Global Rare Neurological Disease Treatment Market Company Share Analysis
11.2. Global Rare Neurological Disease Treatment Market Competition Landscape
11.3. Global Rare Neurological Disease Treatment Market Company Profiles
11.3.1. Pfizer Inc.
11.3.2. Allergan Plc
11.3.3. Novartis AG
11.3.4. Bayer Aktiengesellschaft
11.3.5. Medtronic Plc
11.3.6. Sanofi
11.3.7. Johnson & Johnson
11.3.8. Teva Pharmaceutical Industries Limited
11.3.9. Jazz Pharmaceuticals
11.3.10. EMD Serono, Inc.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report